Australia markets closed

CABA Aug 2024 10.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.7000-11.4400 (-80.91%)
As of 02:31PM EDT. Market open.
Full screen
Previous close14.1400
Open2.7000
Bid2.0000
Ask5.0000
Strike10.00
Expiry date2024-08-16
Day's range2.7000 - 2.7000
Contract rangeN/A
Volume25
Open interest1
  • GlobeNewswire

    Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

    – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients’ specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all

  • GlobeNewswire

    Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

    PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY. A live webcast of the

  • Simply Wall St.

    We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...